- The SARS-CoV-2 outbreak: What we know, Di Wu, International Journal of Infectious Diseases, March 12, 2020 https://www.ijidonline.com/article/S1201-9712(20)30123-5/fulltext [↩]
- Emerging threats from zoonotic coronavirus from SARS and MERS to 2019 -nCoV, Journal of Microbiology, Immunology, and infection, February 2020, https://www.researchgate.net/publication/339025604_Emerging_threats_from_zoonotic_coronaviruses-from_SARS_and_MERS_to_2019-nCoV [↩]
- https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020 [↩]
- Detection of SARS-CoV-2 in different types of Clinical Specimens, Wenling Wang, Yanli Xu, Ruqin Gao; JAMA, 11 March 2020 https://jamanetwork.com/journals/jama/fullarticle/2762997 [↩]
- Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1, The New England Journal of Medicine, March 17, 2020 https://www.nejm.org/doi/full/10.1056/NEJMc2004973 [↩]
- https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome_coronavirus [↩]
- https://en.wikipedia.org/wiki/Middle_East_respiratory_syndrome-related_coronavirus#Evolution [↩]
- An updated estimation of risk of transmission of novel coronavirus (2019-nCoV), Biao Tang, et al., Infectious Disease Modelling, Volume 5, 2020, Pg. 248 – 255 https://www.sciencedirect.com/science/article/pii/S246804272030004X [↩]
- A novel coronavirus from patients with pneumonia in China, 2019, Na Zhu et al., The New England Journal of Medicine, February 20, 2020 https://www.nejm.org/doi/full/10.1056/NEJMoa2001017 [↩]
- Epidemiology, Genetic Recombination, Pathogenesis of Coronavirus, Shou Su et al., Trends in Microbiology, Vol. 24, Issue 6, June 2016 [↩]
- The Spike Protein of SARS-CoV- a target for vaccine and therapeutic development, Lanying Du et al., Nature Review Microbiology, 7 (3), 226-36, March 2009 https://pubmed.ncbi.nlm.nih.gov/19198616/ [↩]
- SARS-CoV-2 Cell entry depends on ACE-2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Markus Hoffmann et al., Cell, 5th march 2020 https://www.sciencedirect.com/science/article/pii/S0092867420302294 [↩] [↩]
- Genomic Characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Prof. Roujian et al., The Lancet, January 30, 2020 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30251-8/fulltext [↩]
- Cryo-EM structure of 2019-nCoV spike in the prefusion conformation, Daniel Wrapp et al., Science, 13 March 2020, https://science.sciencemag.org/content/367/6483/1260 [↩]
- Structure, Function and Antigenicity of the SARS-CoV-2 spike glycoprotein, Alexandra C. Walls, Cell, 9th March 2020, https://www.sciencedirect.com/science/article/pii/S0092867420302622 [↩] [↩]
- Why does coronavirus spread so easily between people? Smriti Mallapaty, 06, March 2020 https://www.nature.com/articles/d41586-020-00660-x [↩]
- LY6E impairs coronavirus fusion and confers immune control of viral disease, Stephanie Pfaender et al., Cold spring harbour laboratory, https://www.biorxiv.org/content/10.1101/2020.03.05.979260v1 [↩]
- Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV, Xiuyuan Ou et al., Nature Communications, 27th March 2020, https://www.nature.com/articles/s41467-020-15562-9 [↩]
- Beating COVID-19: Insights and strategies for new vaccines and therapies, Cynthia Liu, 19th March 2020, CAS, a division of the American Chemical Society, https://www.cas.org/blog/beating-covid-19 [↩]
- Drug repositioning: identifying and developing new uses for existing drugs, Ted T. Ashburn and Karl B. Thor, Nature Reviews Drug Discovery, Volume 3, 2004 https://www.nature.com/articles/nrd1468 [↩]
- Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Yadi Zhou et al., Cell Discovery, 2020 https://www.nature.com/articles/s41421-020-0153-3 [↩]
- WHO launches global megatrial of the four most promising coronavirus treatments, Kai Kupferschmidt, Jon Cohen, 22nd March 2020, https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments [↩] [↩]
- https://en.wikipedia.org/wiki/Small_molecule [↩]
- https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/what-are-biologics-questions-and-answers [↩]
- https://search2.relecura.com/index.php/taxonomy/loadPublicTaxonomy/186541b4-5c80-11ea-919d-023ada72e4ef [↩]
- http://www.technovigil.com/report.php [↩]
- Effects of Chloroquine on viral infections: an old drug against today’s diseases, Dr. Adrea Savarino, The Lancet Infectious Diseases, Vol.3, Issue 11, November 2003, https://www.sciencedirect.com/science/article/pii/S1473309903008065 [↩]
- The hydroxychloroquine and Azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial, Philippe Gautret, International Journal of Antimicrobial agents, 20 March 2020, https://pubmed.ncbi.nlm.nih.gov/32205204/ [↩]
- The hunt for COVID-19 drugs, Debora Mackenzie, New Scientist, 13 March 2020, https://www.newscientist.com/issue/3273/ [↩]
- Effective Treatment of Severe COVID-19 patients with Tocilizumab, Xiaoling Xu et al., chinaXiv [↩]
- COVID-19: combining antiviral and anti-inflammatory treatments, Justin Stebbing et al., 27th February 2020, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30132-8/fulltext [↩]
- Potent coronavirus drug candidate designed using 3D structure of key viral enzyme, Anthony King, Royal Society of Chemistry, 27th march 2020 https://www.chemistryworld.com/news/potent-coronavirus-drug-candidate-designed-using-3d-structure-of-key-viral-enzyme/4011411.article [↩]